Cathie Wood Pounces On Peter Thiel-Backed Bullish Stock After Wild IPO Surge: Ark Buys Stock Worth $172.22 Million - ARK Fintech Innovation ETF ( BATS:ARKF ) , ARK Innovation ETF ( BATS:ARKK )
On Wednesday, Cathie Wood-led Ark Invest made significant trades involving Bullish BLSH and Shopify Inc SHOP.
908 Devices ( MASS ) Q2 Revenue Jumps 14%
908 Devices ( NASDAQ:MASS ) , a specialist in handheld chemical analysis devices, reported its second-quarter 2025 financial results on August 5, 2025. Revenue ( GAAP ) increased to $13.0 million, surpassing Wall Street expectations of $12.17 million. This marked a 14% rise from the prior year's ...
908 Devices Inc. ( MASS ) Reports Q2 Loss, Tops Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of -12.50% and +7.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
WALTHAM, Mass., July 29, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2025, covering the three- and six- month periods ended June 30, 2025.
Innovation ETF ( ARKK ) Hits New 52-Week High
Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.
908 Devices ( MASS ) Upgraded to Buy: Here's What You Should Know
908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why 908 Devices Stock Rocketed More Than 18% Higher This Week
A deal agreed in a far-off country was the spark that ignited chemical analysis device maker 908 Devices ( NASDAQ: MASS ) this week. The company's stock burned hot, finishing the period over 18% higher in price, according to data compiled by S&P Global Market Intelligence.Before market open on ...
All You Need to Know About 908 Devices ( MASS ) Rating Upgrade to Buy
908 Devices (MASS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bet On 4 Low-Beta Stocks BWB, LRN, MASS & PM Despite Tariff Truce
It is imperative to build a portfolio of low-beta stocks in a volatile market. Bridgewater Bancshares, Stride, 908 Devices, and Philip Morris are well-positioned to gain.
908 Devices Inc. ( MASS ) Reports Q1 Loss, Misses Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of 18.52% and 2.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Inogen ( INGN ) Reports Q1 Loss, Tops Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of 51.92% and 3.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Lucid Diagnostics Inc. ( LUCD ) Report Negative Earnings Next Week? What You Should Know
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
908 Devices Inc. ( MASS ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical ( AVNS ) Q1 Earnings and Revenues Top Estimates
Avanos Medical (AVNS) delivered earnings and revenue surprises of 36.84% and 2.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
Mettler-Toledo International's Q1 results reflect growth in the Laboratory business, a decline in Industrial, and continued weakness in the Food Retail segment.
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Repligen Reports First Quarter 2025 Financial Results
WALTHAM, Mass., April 29, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025.
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.
The Zacks Analyst Blog Highlights Fidelity NASDAQ Composite Index ETF, ThredUp, 908 Devices, Logility Supply Chain, Palomar and EZCORP
Fidelity NASDAQ Composite Index ETF, ThredUp, 908 Devices, Logility Supply Chain, Palomar and EZCORP are included in this Analyst Blog.
Repligen ( RGEN ) Moves 3.7% Higher: Will This Strength Last?
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
5 Top-Ranked Stocks of Nasdaq ETF Beating the Bear Market
The tech-focused Nasdaq officially entered bear market territory on Friday, falling over 20% from its December peak.
New Strong Buy Stocks for April 1st
AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.
Best Momentum Stocks to Buy for March 13th
BK, TKOMY and MASS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13, 2025.
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - 908 Devices ( NASDAQ:MASS ) , Repligen ( NASDAQ:RGEN )
908 Devices sold its desktop portfolio to Repligen for $70 million, reducing $20 million in annual operating losses. 908 Devices expects 2025 revenue of $53 million-$55 million, with EBITDA positivity by Q4 2025. Every week, our Whisper Index uncovers five overlooked stocks with big breakout ...
908 Devices Inc. ( MASS ) Reports Q4 Loss, Tops Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of 8.57% and 10.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Portfolio includes PAT devices for real-time process monitoring, control and analysis Portfolio includes PAT devices for real-time process monitoring, control and analysis ...
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - 908 Devices ( NASDAQ:MASS ) , Repligen ( NASDAQ:RGEN )
WALTHAM, Mass. and BOSTON, March 04, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc.
Teleflex ( TFX ) Surpasses Q4 Earnings Estimates
Teleflex (TFX) delivered earnings and revenue surprises of 0.78% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Alphatec ( ATEC ) Reports Q4 Loss, Tops Revenue Estimates
Alphatec (ATEC) delivered earnings and revenue surprises of -27.78% and 1.94%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. ( MASS ) Reports Q3 Loss, Lags Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of 20.69% and 8.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical ( GMED ) Beats Q3 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of 27.69% and 3.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. ( MASS ) Reports Q2 Loss, Tops Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of 5.88% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. ( CLPT ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: 908 Devices Inc. ( MASS ) Q2 Earnings Expected to Decline
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 133.69% Upside in 908 Devices ( MASS ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 133.7% in 908 Devices (MASS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
908 Devices ( MASS ) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
908 Devices (MASS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
$2.8M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying - Aon ( NYSE:AON )
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
908 Devices Inc. ( MASS ) Reports Q1 Loss, Tops Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of 10.81% and 6.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Holdings ( IQV ) Reports Next Week: Wall Street Expects Earnings Growth
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intuitive Surgical, Inc. ( ISRG ) Q1 Earnings and Revenues Top Estimates
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 7.14% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood Sells $13.15M Worth Of Coinbase Shares Amid Bitcoin Flirting With All-Time High Levels - Shops For Palantir Stock Instead - Coinbase Glb ( NASDAQ:COIN )
On Thursday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc COIN and Palantir Technologies Inc PLTR being the most prominent. Ark Invest sold a substantial number of Coinbase shares across three of its funds: ARK Innovation ETF ARKK, ARK Next Generation Internet ...
Nevro ( NVRO ) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 70% and 0.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. ( MASS ) Upgraded to Buy: What Does It Mean for the Stock?
908 Devices Inc. (MASS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street
Wall Street is uber-bullish on these two Ark Invest holdings.
How Much Upside is Left in 908 Devices Inc. ( MASS ) ? Wall Street Analysts Think 100.39%
The consensus price target hints at a 100.4% upside potential for 908 Devices Inc. (MASS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Microfluidic Market for Healthcare Application to grow by USD 43.27 billion from 2022 to 2027 | Growth Driven by the ... - PR Newswire
Microfluidic Market for Healthcare Application to grow by USD 43.27 billion from 2022 to 2027 | Growth Driven by the ... PR ...
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders.
908 Devices Inc. ( MASS ) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) delivered earnings and revenue surprises of 12.12% and 16.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical ( SWAV ) Misses Q2 Earnings Estimates
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -12.64% and 3.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs ( MLAB ) Surpasses Q1 Earnings Estimates
Mesa Labs (MLAB) delivered earnings and revenue surprises of 5.99% and 2.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
